Immuron Limited
ASX:IMC.AX
0.08 (AUD) • At close October 22, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Immuron Limited |
Symbool | IMC.AX |
Munteenheid | AUD |
Prijs | 0.077 |
Beurswaarde | 17,644,165 |
Dividendpercentage | 0% |
52-weken bereik | 0.065 - 0.17 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Steven George Lydeamore CPA, CPA, M.B.A., MBA |
Website | https://www.immuron.com.au |
An error occurred while fetching data.
Over Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)